# Progress Note 06 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Satchel Paige (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML047-SYN
- Date: 2026-10-27
- Fictional facility: St. Posthumous Health Center
- Fictional author: Delphine Whitaker-Osei, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Fifteen-week review after an exacerbation and pulmonary rehabilitation. **S**

## History of present illness

Mr. Paige returns five weeks after a moderate exacerbation treated at home with prednisone and doxycycline, and five days after finishing pulmonary rehabilitation (twenty sessions). He used his action plan well: he called the clinic the morning his breathing worsened and started treatment that day. He is back to walking to the store and beyond without stopping and uses albuterol about twice a week. He takes his inhaler every morning. He had his vaccines at the wellness visit three weeks ago with only a sore arm. His aortic ultrasound a week ago showed no aneurysm, and his hepatitis C and hepatitis B tests were negative. He asked whether he needs another inhaler after the flare-up. **S**

| Element | Detail |
|---|---|
| Symptoms | CAT 11; mMRC 1 |
| Exacerbations | One moderate, five weeks ago, treated at home; no hospital stay |
| Six-minute walk | 425 m, from 360; lowest saturation 92 percent |
| Mood | PHQ-9 2 |
| Screening results | Aorta 2.4 cm; hepatitis C and B negative |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Respiratory | Positive | Usual mild breathlessness on hills; little sputum; no wheeze |
| Cardiovascular | Negative | No chest pain, palpitations or ankle swelling |
| Musculoskeletal | Negative | No muscle aches |
| Psychiatric | Negative | Mood good; PHQ-9 2 |

4 systems reviewed. **S**

## Current medications

- Albuterol 90 micrograms per inhalation metered-dose inhaler with a spacer, two inhalations every four hours as needed for breathlessness **S**
- Umeclidinium 62.5 micrograms with vilanterol 25 micrograms dry powder inhaler (a LAMA with a LABA), one inhalation once a day **S**
- Atorvastatin 20 mg tablet once a day **S**

## Allergies

- No known allergy **S**

## Objective

BP 128/78 mmHg; pulse 76 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 95% on room air; weight 83.4 kg; BMI 22.9 kg/m². All vital signs are synthetic.

Six-minute walk distance: 425 m; PHQ-9: 2. All results are synthetic.

## Change since baseline

- PHQ-9: 5 at baseline, 2 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 128/78, pulse 76, oxygen saturation 95 percent on room air |
| Respiratory | Reduced breath sounds; no wheeze or crackles |
| Cardiovascular | Regular rhythm; no edema |
| Inhaler technique | Correct |

All examination findings are synthetic. **S**

## Assessment and plan

1. **COPD, GOLD grade 2, group B** (J44.9). One moderate exacerbation in the past year keeps him in group B (group E needs two moderate exacerbations or one hospital stay). With eosinophils of 0.08 x 10^3/uL an inhaled corticosteroid is unlikely to help and would raise the risk of pneumonia; azithromycin or roflumilast is for repeated exacerbations despite maintenance therapy. So no change: he stays on the LAMA with LABA. Rehabilitation lengthened his walk from 360 to 425 m and his CAT fell from 18 to 11. **S**
   - Continue umeclidinium-vilanterol and albuterol as needed.
   - Home exercise program three times a week, with a maintenance class at the rehabilitation center.
   - Action plan reviewed: call the clinic the same day for a flare, as he did this time; no standby steroid prescription for now.
   - Spirometry and low-dose CT in the summer.
2. **Hyperlipidemia on atorvastatin** (E78.5). Controlled; no muscle symptoms. **S**
   - Lipid panel yearly.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Symptoms: CAT and mMRC dyspnea scale | Every visit | Completed today | CAT 11; mMRC 1 |
| Survey | Exacerbations in the past 12 months (moderate and severe) and GOLD group | Every visit | Completed today | One moderate exacerbation in the past year; still group B |
| Examination | Pulse oximetry at rest | Every visit | Completed today | 95 percent on room air |
| Laboratory | Spirometry: post-bronchodilator FEV1/FVC and FEV1 % predicted (race-neutral GLI Global) | At diagnosis, then at least yearly or with a clear change | Up to date | Next spirometry in the summer, a year after diagnosis |
| Laboratory | Blood eosinophil count | At baseline and when an inhaled corticosteroid is considered | Up to date | 0.08 x 10^3/uL at intake; an inhaled corticosteroid considered after the exacerbation and not advised |
| Self-management | Smoking status and cessation support | Every visit | Completed today | Smoke-free |
| Examination | BMI and nutrition | Every visit | Completed today | BMI 22.9; weight steady after the steroid course |
| Medication safety | Inhaler technique, adherence and side effects (dry mouth, urinary retention) | Every visit | Completed today | Correct technique; no missed doses |
| Examination | ECG and cardiovascular risk | At baseline; reassess after exacerbations | Deferred | The ECG that the CMID protocol calls for after an exacerbation was not done at the sick visit. He has had no chest pain or palpitations, and today's ECG is unchanged from intake, so no harm is evident. Corrective action: ECG done today and added to the clinic's exacerbation visit template |
| Referral | Pulmonary rehabilitation | Offer when mMRC is 2 or more, or CAT 10 or more; within three weeks of a hospital discharge for an exacerbation | Completed today | Twenty sessions completed five days ago; maintenance class and home program |
| Examination | Six-minute walk test | At rehabilitation entry and exit, and for oxygen assessment | Completed today | 425 m at rehabilitation exit; lowest saturation 92 percent |
| Examination | Long-term oxygen assessment | When resting PaO2 is 55 mm Hg or less (60 with cor pulmonale or polycythemia) or saturation 88 percent or less, confirmed twice | Not indicated | Saturation 95 percent at rest and 92 percent at its lowest on walking |
| Self-management | Written and spoken COPD action plan | At diagnosis, reviewed after each exacerbation | Completed today | Used well at the exacerbation; reviewed |
| Self-management | Vaccines: influenza, pneumococcal, RSV, COVID-19, Tdap, zoster | Yearly review | Up to date | Influenza, RSV, COVID-19 and the first zoster dose three weeks ago; PCV20 and Tdap at intake; second zoster dose due |
| Imaging | Low-dose CT lung cancer screening | Yearly at 50 to 80 with 20 or more pack-years, while within fifteen years of quitting | Up to date | Next in the summer |
| Medication safety | Statin safety: muscle symptoms | Every visit | Completed today | No muscle aches |
| Survey | Mood (PHQ-9) | At intake and when symptoms change | Completed today | 2, from 5, with item 9 scored 0 |

## Goal progress

- Find the cause of the breathlessness. Outcome by 2026-07-28: COPD confirmed by spirometry (post-bronchodilator FEV1/FVC 0.58); heart failure unlikely (NT-proBNP 92, normal ECG); alpha-1 antitrypsin normal. **S**
- Walk farther with less breathlessness. Outcome by 2026-10-27: Six-minute walk 360 to 425 m after rehabilitation; CAT 18 to 11. **S**
- Fewer and milder flare-ups, treated early. In progress; target 2027-07-14. **S**
- LDL below 100 mg/dL. Outcome by 2026-09-08: LDL 148 to 86 mg/dL on atorvastatin 20 mg. **S**
- Vaccines up to date. Outcome by 2026-10-06: PCV20 and Tdap at intake; influenza, RSV, COVID-19 and the first zoster dose at the wellness visit. **S**

## Guideline basis

- Global Strategy for the Prevention, Diagnosis and Management of COPD: 2025 Report (2025), Global Initiative for Chronic Obstructive Lung Disease
- Race and Ethnicity in Pulmonary Function Test Interpretation: An Official American Thoracic Society Statement (2023), American Thoracic Society (American Journal of Respiratory and Critical Care Medicine 2023;207(8):978-995)
- CMID: Clinical Monitoring Intelligence Database, COPD and hyperlipidemia monographs (2026), Aether Forge
- Pulmonary Rehabilitation for Adults with Chronic Respiratory Disease: An Official American Thoracic Society Clinical Practice Guideline (2023), American Thoracic Society (American Journal of Respiratory and Critical Care Medicine 2023;208(4):e7-e26)
- Home Oxygen Therapy for Adults with Chronic Lung Disease: An Official American Thoracic Society Clinical Practice Guideline (2020), American Thoracic Society (American Journal of Respiratory and Critical Care Medicine 2020;202(10):e121-e141)
- A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation (LOTT) (2016), Long-Term Oxygen Treatment Trial Research Group (New England Journal of Medicine 2016;375(17):1617-1627)
- Racial Bias in Pulse Oximetry Measurement (2020), Sjoding MW, et al. (New England Journal of Medicine 2020;383(25):2477-2478)
- Lung Cancer: Screening (2021), U.S. Preventive Services Task Force
- Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication (2022), U.S. Preventive Services Task Force
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force

## Follow-up

- Review in three months, sooner for a flare. Spirometry and low-dose CT next summer. Second zoster dose in one to five months. Next wellness visit in a year. **S**

